Identification

Name
Nimesulide
Accession Number
DB04743
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.

Structure
Thumb
Synonyms
Not Available
External IDs
R 805 / R-805
International/Other Brands
Ainex / Aulin / Coxtal / Eskaflam / Mesulid / Nilsid / Nimalox / Nimside / Nise / Octaprin / Sintalgin / Sulide
Categories
UNII
V4TKW1454M
CAS number
51803-78-2
Weight
Average: 308.31
Monoisotopic: 308.046692194
Chemical Formula
C13H12N2O5S
InChI Key
HYWYRSMBCFDLJT-UHFFFAOYSA-N
InChI
InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
IUPAC Name
N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
SMILES
CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O

Pharmacology

Indication

For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.

Pharmacodynamics

Food, gender and advanced age have negligible effects on nimesulide pharmacokinetics.

Mechanism of action

The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UGroup IIE secretory phospholipase A2Not AvailableHuman
ULactotransferrinNot AvailableHuman
Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding

>97.5%

Metabolism

Hepatic. Extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active).

Route of elimination

Renal (50%), fecal (29%)

Half life

1.8–4.7 hours

Clearance
Not Available
Toxicity

Oral TDLO (human): 1.429 mg/kg; Oral TDLO (woman): 2 mg/kg; Oral LD50 (rat): 200 mg/kg; Oral LD50 (mouse): 392 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with (R)-warfarin.Experimental
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with (S)-Warfarin.Experimental, Investigational
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with 4-hydroxycoumarin.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Nimesulide.Investigational
AbciximabNimesulide may increase the anticoagulant activities of Abciximab.Approved
AcebutololNimesulide may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nimesulide.Approved, Vet Approved
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Nimesulide.Approved, Investigational, Withdrawn
AlaproclateAlaproclate may increase the antiplatelet activities of Nimesulide.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Nimesulide.Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of gastrointestinal irritation can be increased when Alclometasone is combined with Nimesulide.Approved
AlcuroniumNimesulide may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneThe risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Nimesulide.Experimental, Investigational
Alendronic acidThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Alendronic acid.Approved
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Nimesulide.Approved, Investigational
AliskirenThe risk or severity of renal failure and hypertension can be increased when Nimesulide is combined with Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aloxiprin.Experimental
AlprenololNimesulide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nimesulide.Approved, Investigational
AlteplaseNimesulide may increase the anticoagulant activities of Alteplase.Approved
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Nimesulide.Approved, Investigational
AmcinonideThe risk or severity of gastrointestinal irritation can be increased when Amcinonide is combined with Nimesulide.Approved
AmediplaseNimesulide may increase the anticoagulant activities of Amediplase.Investigational
AmikacinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Amiloride.Approved
AminophenazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Nimesulide can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Nimesulide.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Nimesulide.Approved
AmobarbitalThe metabolism of Nimesulide can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nimesulide.Approved
Amphotericin BNimesulide may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Nimesulide can be decreased when combined with Amprenavir.Approved, Investigational
AnagrelideNimesulide may increase the anticoagulant activities of Anagrelide.Approved
AncrodNimesulide may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideNimesulide may increase the antiplatelet activities of Andrographolide.Investigational
AnisodamineNimesulide may decrease the antihypertensive activities of Anisodamine.Investigational
AnistreplaseNimesulide may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nimesulide.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Nimesulide can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apixaban.Approved
ApramycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Nimesulide can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Arbekacin.Approved, Investigational
ArdeparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNimesulide may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Nimesulide.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Nimesulide.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Nimesulide.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Nimesulide.Approved
AstaxanthinNimesulide may increase the anticoagulant activities of Astaxanthin.Investigational
AtazanavirThe metabolism of Nimesulide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololNimesulide may decrease the antihypertensive activities of Atenolol.Approved
AtracuriumNimesulide may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateNimesulide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Nimesulide.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Nimesulide.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Nimesulide.Approved, Investigational
BarbexacloneThe metabolism of Nimesulide can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nimesulide can be increased when combined with Barbital.Illicit
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Nimesulide.Approved, Investigational
BefunololNimesulide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Bekanamycin.Experimental
BemiparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Benazeprilat.Experimental
BendazacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nimesulide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benoxaprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Nimesulide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nimesulide.Approved, Withdrawn
BeraprostNimesulide may increase the antiplatelet activities of Beraprost.Investigational
BesifloxacinNimesulide may increase the neuroexcitatory activities of Besifloxacin.Approved
BetamethasoneThe risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Nimesulide.Approved, Vet Approved
BetaxololNimesulide may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Nimesulide.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Nimesulide.Approved, Investigational
BevantololNimesulide may decrease the antihypertensive activities of Bevantolol.Approved
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Nimesulide.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Nimesulide.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nimesulide.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Nimesulide.Approved
BisoprololNimesulide may decrease the antihypertensive activities of Bisoprolol.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Nimesulide.Approved
BivalirudinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Nimesulide can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololNimesulide may decrease the antihypertensive activities of Bopindolol.Approved
BosentanThe serum concentration of Nimesulide can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Nimesulide.Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Nimesulide.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Nimesulide.Approved, Investigational
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Nimesulide.Approved
BrinaseNimesulide may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nimesulide.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Nimesulide.Approved, Investigational
BucindololNimesulide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Nimesulide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bufexamac.Approved, Experimental
BuflomedilNimesulide may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolNimesulide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Nimesulide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Nimesulide.Investigational
BupranololNimesulide may decrease the antihypertensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Nimesulide.Approved
ButylphthalideNimesulide may increase the antiplatelet activities of Butylphthalide.Investigational
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Nimesulide.Experimental
Calcium AcetateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Nimesulide.Experimental
Candesartan cilexetilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Nimesulide.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Nimesulide.Experimental
CangrelorNimesulide may increase the antiplatelet activities of Cangrelor.Approved
CapreomycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Capreomycin.Approved
CaptoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Captopril.Approved
CarbamazepineThe metabolism of Nimesulide can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Nimesulide is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nimesulide.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nimesulide.Approved, Investigational
CarbutamideThe protein binding of Carbutamide can be decreased when combined with Nimesulide.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nimesulide.Approved, Vet Approved, Withdrawn
CarteololNimesulide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolNimesulide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Nimesulide.Approved, Investigational, Nutraceutical, Vet Approved
CefacetrileThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Nimesulide.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Nimesulide.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Nimesulide.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Nimesulide.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Nimesulide.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Nimesulide.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Nimesulide.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Nimesulide.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Nimesulide.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Nimesulide.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Nimesulide.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Nimesulide.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Nimesulide.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Nimesulide.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Nimesulide.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Nimesulide.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Nimesulide.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Nimesulide.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Nimesulide.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Nimesulide.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Nimesulide.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Nimesulide.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Nimesulide.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Nimesulide.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Nimesulide.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Nimesulide.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Nimesulide.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Nimesulide.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Nimesulide.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nimesulide.Approved, Investigational
CeliprololNimesulide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Cephalothin Group.Experimental
CeritinibThe serum concentration of Nimesulide can be increased when it is combined with Ceritinib.Approved
CertoparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Certoparin.Approved, Investigational
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
ChlorotrianiseneNimesulide may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Nimesulide.Approved, Investigational, Vet Approved
ChlorpropamideThe protein binding of Chlorpropamide can be decreased when combined with Nimesulide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nimesulide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nimesulide.Approved
CiclesonideThe risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Nimesulide.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Nimesulide.Investigational
CilazaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Cilazapril.Approved
CilostazolCilostazol may increase the antiplatelet activities of Nimesulide.Approved, Investigational
CimetidineThe serum concentration of Nimesulide can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cimicoxib.Investigational
CinoxacinNimesulide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinNimesulide may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisatracuriumNimesulide may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Nimesulide.Approved
CitalopramCitalopram may increase the antiplatelet activities of Nimesulide.Approved
ClarithromycinThe metabolism of Nimesulide can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of gastrointestinal irritation can be increased when Clobetasol is combined with Nimesulide.Approved, Investigational
Clobetasol propionateThe risk or severity of gastrointestinal irritation can be increased when Clobetasol propionate is combined with Nimesulide.Approved
ClobetasoneThe risk or severity of gastrointestinal irritation can be increased when Clobetasone is combined with Nimesulide.Approved
ClocortoloneThe risk or severity of gastrointestinal irritation can be increased when Clocortolone is combined with Nimesulide.Approved
Clodronic AcidThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Nimesulide.Approved
ClonixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimesulide.Approved
CloprednolThe risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Nimesulide.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nimesulide.Vet Approved
CloranololNimesulide may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenNimesulide may increase the antiplatelet activities of Cloricromen.Experimental
ClorindioneThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Clorindione.Experimental
ClotrimazoleThe metabolism of Nimesulide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Nimesulide.Approved
CobicistatThe metabolism of Nimesulide can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Nimesulide.Approved, Vet Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Nimesulide is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nimesulide.Approved, Investigational
Conjugated estrogensNimesulide may increase the thrombogenic activities of Conjugated estrogens.Approved
CorticotropinThe risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Nimesulide.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Cortisone acetate is combined with Nimesulide.Approved, Investigational
CortivazolThe risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Nimesulide.Investigational
CrizotinibThe metabolism of Nimesulide can be decreased when combined with Crizotinib.Approved
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Nimesulide.Approved
CurcuminThe metabolism of Nimesulide can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nimesulide.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Nimesulide is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Nimesulide.Approved
Dabigatran etexilateNimesulide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Nimesulide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinNimesulide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNimesulide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolThe metabolism of Nimesulide can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nimesulide.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Nimesulide.Investigational
DarexabanThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Darexaban.Investigational
DarunavirThe metabolism of Nimesulide can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Nimesulide.Approved, Investigational
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Nimesulide.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Nimesulide is combined with Deferasirox.Approved, Investigational
DefibrotideNimesulide may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Nimesulide.Approved, Investigational
DelaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Delapril.Investigational
DelavirdineThe metabolism of Nimesulide can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dersalazine.Investigational
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Nimesulide.Approved
DesirudinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Desirudin.Approved
DesmopressinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Nimesulide is combined with Desmopressin.Approved
DesmoteplaseNimesulide may increase the anticoagulant activities of Desmoteplase.Investigational
DesonideThe risk or severity of gastrointestinal irritation can be increased when Desonide is combined with Nimesulide.Approved, Investigational
DesoximetasoneThe risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Nimesulide.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Nimesulide.Approved, Investigational
DexamethasoneThe serum concentration of Nimesulide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone isonicotinate is combined with Nimesulide.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Nimesulide.Experimental
DextranThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Dextran.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Nimesulide.Approved
DibekacinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Dibekacin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nimesulide.Approved, Vet Approved
DicoumarolNimesulide may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolNimesulide may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Nimesulide.Investigational
DiethylstilbestrolNimesulide may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of gastrointestinal irritation can be increased when Diflorasone is combined with Nimesulide.Approved
DifloxacinNimesulide may increase the neuroexcitatory activities of Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nimesulide.Approved, Investigational
DifluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Nimesulide.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of gastrointestinal irritation can be increased when Difluprednate is combined with Nimesulide.Approved
DigoxinNimesulide may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Nimesulide.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nimesulide.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Nimesulide can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nimesulide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nimesulide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nimesulide.Approved
DiphenadioneThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Diphenadione.Experimental
DipyridamoleDipyridamole may increase the antiplatelet activities of Nimesulide.Approved
DitazoleThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ditazole.Approved, Withdrawn
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Nimesulide.Approved
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Nimesulide.Approved
DoxacuriumNimesulide may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Nimesulide.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Nimesulide.Approved, Investigational
DoxycyclineThe metabolism of Nimesulide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Nimesulide.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Nimesulide.Approved, Vet Approved
DrospirenoneThe risk or severity of hyperkalemia can be increased when Nimesulide is combined with Drospirenone.Approved
Drotrecogin alfaNimesulide may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Nimesulide.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Nimesulide.Approved
Edetic AcidThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Nimesulide.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Nimesulide.Approved, Investigational
EnalaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Enalaprilat.Approved
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Nimesulide.Experimental
EnoxacinNimesulide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Nimesulide.Experimental
EnzalutamideThe serum concentration of Nimesulide can be decreased when it is combined with Enzalutamide.Approved
EpanololNimesulide may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolNimesulide may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Nimesulide.Experimental
EplerenoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the antiplatelet activities of Nimesulide.Approved
EprosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Nimesulide.Approved
EptifibatideEptifibatide may increase the antiplatelet activities of Nimesulide.Approved, Investigational
EquolNimesulide may increase the thrombogenic activities of Equol.Investigational
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Nimesulide.Approved
ErythromycinThe metabolism of Nimesulide can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololNimesulide may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Nimesulide.Approved, Investigational
EsmololNimesulide may decrease the antihypertensive activities of Esmolol.Approved
EstradiolNimesulide may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateNimesulide may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateNimesulide may increase the thrombogenic activities of Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateNimesulide may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateNimesulide may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolNimesulide may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedNimesulide may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneNimesulide may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateNimesulide may increase the thrombogenic activities of Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nimesulide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ethenzamide.Experimental
Ethinyl EstradiolNimesulide may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Nimesulide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nimesulide.Approved, Investigational
EtravirineThe serum concentration of Nimesulide can be decreased when it is combined with Etravirine.Approved
FelbinacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Felbinac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Nimesulide.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fenbufen.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Nimesulide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nimesulide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nimesulide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Nimesulide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Nimesulide.Experimental
FibrinolysinNimesulide may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Nimesulide.Approved, Investigational
FirocoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Firocoxib.Experimental, Vet Approved
FleroxacinNimesulide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Floctafenine.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Nimesulide.Investigational
FlucloroloneThe risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Nimesulide.Experimental
FluconazoleThe metabolism of Nimesulide can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Nimesulide.Approved, Investigational
FluindioneThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Fluindione.Approved, Investigational
FlumequineNimesulide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Nimesulide.Approved, Vet Approved
FlunisolideThe risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Nimesulide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinolone Acetonide is combined with Nimesulide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Nimesulide.Approved, Investigational
FluocortinThe risk or severity of gastrointestinal irritation can be increased when Fluocortin is combined with Nimesulide.Experimental
FluocortoloneThe risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Nimesulide.Approved, Withdrawn
FluorometholoneThe risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Nimesulide.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Nimesulide.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Nimesulide.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of gastrointestinal irritation can be increased when Fluperolone is combined with Nimesulide.Experimental
FluprednideneThe risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Nimesulide.Approved, Withdrawn
FluprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Fluprednisolone is combined with Nimesulide.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nimesulide.Vet Approved
FlurandrenolideThe risk or severity of gastrointestinal irritation can be increased when Flurandrenolide is combined with Nimesulide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nimesulide.Approved, Investigational
FluticasoneThe risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Nimesulide.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Nimesulide.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Nimesulide.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Nimesulide.Experimental
FluvoxamineFluvoxamine may increase the antiplatelet activities of Nimesulide.Approved, Investigational
FondaparinuxNimesulide may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
ForasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Nimesulide.Experimental
FormocortalThe risk or severity of gastrointestinal irritation can be increased when Formocortal is combined with Nimesulide.Experimental
FosamprenavirThe metabolism of Nimesulide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nimesulide can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Foscarnet.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nimesulide.Approved, Investigational
FramycetinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Framycetin.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nimesulide can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Gabexate.Investigational
GallamineNimesulide may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideNimesulide may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GarenoxacinNimesulide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNimesulide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nimesulide.Approved, Withdrawn
GemifloxacinNimesulide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Geneticin.Experimental
GentamicinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with GENTAMICIN C1A.Experimental
GliclazideThe protein binding of Gliclazide can be decreased when combined with Nimesulide.Approved
GlipizideThe protein binding of Glipizide can be decreased when combined with Nimesulide.Approved, Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Nimesulide.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Nimesulide.Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nimesulide.Approved, Investigational
GrepafloxacinNimesulide may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Nimesulide is combined with Guacetisal.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Nimesulide.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Nimesulide.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Nimesulide.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Nimesulide.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Nimesulide.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Nimesulide.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Nimesulide.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Nimesulide.Experimental
HalcinonideThe risk or severity of gastrointestinal irritation can be increased when Halcinonide is combined with Nimesulide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of gastrointestinal irritation can be increased when Halometasone is combined with Nimesulide.Experimental
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Nimesulide.Approved
HeparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Heparin.Approved, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Nimesulide.Experimental
HexestrolNimesulide may increase the thrombogenic activities of Hexestrol.Withdrawn
HexobarbitalThe metabolism of Nimesulide can be increased when combined with Hexobarbital.Approved
HydralazineNimesulide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Nimesulide.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone aceponate is combined with Nimesulide.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Nimesulide.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Nimesulide.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone probutate is combined with Nimesulide.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone succinate is combined with Nimesulide.Approved
Hydrocortisone valerateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone valerate is combined with Nimesulide.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nimesulide.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Hydrolyzed Cephalothin.Experimental
HydroxytyrosolNimesulide may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Hygromycin BThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Hygromycin B.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide.Approved
IbudilastNimesulide may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nimesulide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of adverse effects can be increased when Nimesulide is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylNimesulide may increase the antiplatelet activities of Icosapent ethyl.Approved, Investigational, Nutraceutical
IdelalisibThe metabolism of Nimesulide can be decreased when combined with Idelalisib.Approved
IdraparinuxThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Idraparinux.Investigational
IfetrobanNimesulide may increase the antiplatelet activities of Ifetroban.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Nimesulide.Approved
IloprostNimesulide may increase the anticoagulant activities of Iloprost.Approved, Investigational
ImatinibThe metabolism of Nimesulide can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Nimesulide.Approved
Incadronic acidThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Incadronic acid.Approved, Investigational
IndalpineIndalpine may increase the antiplatelet activities of Nimesulide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.Approved
IndenololNimesulide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nimesulide can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Nimesulide.Withdrawn
IrbesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Nimesulide.Approved, Investigational
IsavuconazoleThe serum concentration of Nimesulide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Nimesulide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Isepamicin.Experimental
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Nimesulide.Approved
IsoniazidThe metabolism of Nimesulide can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Isoxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Nimesulide.Approved, Investigational
ItraconazoleThe metabolism of Nimesulide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nimesulide can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Kebuzone.Experimental
KetanserinNimesulide may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Nimesulide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nimesulide.Approved
LabetalolNimesulide may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Nimesulide.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Nimesulide.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Nimesulide.Approved
LandiololNimesulide may decrease the antihypertensive activities of Landiolol.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Nimesulide.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nimesulide.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Nimesulide.Approved, Investigational
LepirudinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Nimesulide.Approved, Investigational
LetaxabanThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Letaxaban.Investigational
LevobetaxololNimesulide may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololNimesulide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNimesulide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Nimesulide.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Nimesulide.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Nimesulide.Approved
LinsidomineNimesulide may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Lisinopril.Approved, Investigational
Lithium cationNimesulide may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Nimesulide.Approved, Investigational
LomefloxacinNimesulide may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lonazolac.Experimental
LopinavirThe metabolism of Nimesulide can be decreased when combined with Lopinavir.Approved
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Nimesulide.Investigational, Withdrawn
LornoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Nimesulide can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Nimesulide.Approved
LoteprednolThe risk or severity of gastrointestinal irritation can be increased when Loteprednol is combined with Nimesulide.Approved
LovastatinThe metabolism of Nimesulide can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nimesulide.Approved, Investigational
LuliconazoleThe serum concentration of Nimesulide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nimesulide can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Nimesulide.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nimesulide.Vet Approved
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Nimesulide.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Nimesulide.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Nimesulide.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nimesulide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nimesulide is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Nimesulide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nimesulide is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Nimesulide.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Nimesulide.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Nimesulide.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.Approved, Vet Approved
MedrysoneThe risk or severity of gastrointestinal irritation can be increased when Medrysone is combined with Nimesulide.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nimesulide.Approved
MelagatranThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Melagatran.Experimental
MelengestrolThe risk or severity of gastrointestinal irritation can be increased when Melengestrol is combined with Nimesulide.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.Approved, Vet Approved
MepindololNimesulide may decrease the antihypertensive activities of Mepindolol.Experimental
MeprednisoneThe risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Nimesulide.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mesalazine.Approved
MestranolNimesulide may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Metamizole.Approved, Investigational, Withdrawn
MethallenestrilNimesulide may increase the thrombogenic activities of Methallenestril.Experimental
MethohexitalThe metabolism of Nimesulide can be increased when combined with Methohexital.Approved
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Nimesulide.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nimesulide.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nimesulide.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Nimesulide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Methyl salicylate.Approved, Vet Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Nimesulide.Approved
MethylphenobarbitalThe metabolism of Nimesulide can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Nimesulide.Approved, Vet Approved
MetipranololNimesulide may decrease the antihypertensive activities of Metipranolol.Approved
MetocurineNimesulide may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideNimesulide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.Approved
MetoprololNimesulide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Nimesulide.Approved
MibefradilThe metabolism of Nimesulide can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Nimesulide can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Micronomicin.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nimesulide.Approved, Experimental
MifepristoneThe serum concentration of Nimesulide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Nimesulide.Approved, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nimesulide.Approved, Vet Approved
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Nimesulide.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nimesulide.Approved
MitotaneThe serum concentration of Nimesulide can be decreased when it is combined with Mitotane.Approved
MivacuriumNimesulide may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Nimesulide can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Nimesulide.Approved, Vet Approved
Mometasone furoateThe risk or severity of gastrointestinal irritation can be increased when Mometasone furoate is combined with Nimesulide.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Morniflumate.Approved
MoxestrolNimesulide may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinNimesulide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Nimesulide.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Nimesulide.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Nimesulide.Approved
NadololNimesulide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Nafamostat.Approved, Investigational
NafcillinThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilNimesulide may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidNimesulide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxoneThe metabolism of Nimesulide can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nimesulide.Approved, Vet Approved
NeamineThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Neamine.Experimental
NebivololNimesulide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Nimesulide.Approved, Withdrawn
NelfinavirThe metabolism of Nimesulide can be decreased when combined with Nelfinavir.Approved
NemonoxacinNimesulide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nimesulide.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Nimesulide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Nimesulide can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Nimesulide.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Nimesulide.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Nimesulide.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nimesulide.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Nimesulide.Experimental
NilotinibThe metabolism of Nimesulide can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Nimesulide.Approved, Investigational
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Nimesulide.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Nimesulide.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nimesulide.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nitroaspirin.Investigational
NitroprussideNimesulide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorfloxacinNimesulide may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Nimesulide.Approved
NS-398The risk or severity of adverse effects can be increased when Nimesulide is combined with NS-398.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Obinutuzumab.Approved, Investigational
OfloxacinNimesulide may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Nimesulide.Approved, Investigational
OlaparibThe metabolism of Nimesulide can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Nimesulide.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nimesulide.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Nimesulide is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Nimesulide.Approved, Nutraceutical
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Nimesulide.Experimental
OrbifloxacinNimesulide may increase the neuroexcitatory activities of Orbifloxacin.Vet Approved
OsimertinibThe serum concentration of Nimesulide can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Nimesulide.Approved
Oxolinic acidNimesulide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNimesulide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Nimesulide.Investigational, Withdrawn
PalbociclibThe serum concentration of Nimesulide can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Nimesulide.Approved
PamidronateThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Pamidronate.Approved
PancuroniumNimesulide may increase the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneThe risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Nimesulide.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Parecoxib.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Nimesulide.Approved
ParnaparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Nimesulide.Approved, Investigational
PazufloxacinNimesulide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNimesulide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNimesulide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Nimesulide.Experimental
PentamidineThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Nimesulide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Nimesulide.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nimesulide.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Nimesulide.Approved, Investigational
PerindoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Perindoprilat.Experimental
PhenindioneThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Nimesulide can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Nimesulide.Approved, Withdrawn
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Nimesulide.Approved
PhenprocoumonThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Phenprocoumon.Approved, Investigational
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Nimesulide.Approved
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nimesulide.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nimesulide.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nimesulide.Approved
PicotamideNimesulide may increase the antiplatelet activities of Picotamide.Experimental
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Nimesulide.Approved
PindololNimesulide may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PipecuroniumNimesulide may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidNimesulide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nimesulide.Approved
Piromidic acidNimesulide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Nimesulide.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Nimesulide.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Nimesulide.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Nimesulide.Approved
Polyestradiol phosphateNimesulide may increase the thrombogenic activities of Polyestradiol phosphate.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nimesulide.Approved, Vet Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nimesulide.Approved
PosaconazoleThe metabolism of Nimesulide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Nimesulide.Approved, Investigational
Potassium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololNimesulide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateNimesulide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pranoprofen.Experimental, Investigational
PrasugrelPrasugrel may increase the antiplatelet activities of Nimesulide.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Nimesulide.Approved
PrednicarbateThe risk or severity of gastrointestinal irritation can be increased when Prednicarbate is combined with Nimesulide.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Nimesulide.Approved, Vet Approved
PrednisoneThe risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Nimesulide.Approved, Vet Approved
PrednylideneThe risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Nimesulide.Experimental
PrimidoneThe metabolism of Nimesulide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidProbenecid may decrease the excretion rate of Nimesulide which could result in a higher serum level.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Nimesulide.Approved, Vet Approved
PromestrieneNimesulide may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Propacetamol.Approved, Investigational
PropafenoneNimesulide may decrease the antihypertensive activities of Propafenone.Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nimesulide.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nimesulide.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Nimesulide.Approved, Investigational
PropranololNimesulide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nimesulide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nimesulide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nimesulide.Vet Approved
Protein CNimesulide may increase the anticoagulant activities of Protein C.Approved
Protein S humanThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Protocatechualdehyde.Approved
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Nimesulide.Approved
PrulifloxacinNimesulide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Puromycin.Experimental
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Nimesulide.Approved
QuinaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Quinaprilat.Experimental
QuinestrolNimesulide may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nimesulide.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Nimesulide.Approved, Investigational
QuinineThe metabolism of Nimesulide can be increased when combined with Quinine.Approved
RamatrobanNimesulide may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Ramiprilat.Experimental
RapacuroniumNimesulide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Nimesulide.Investigational
RelcovaptanNimesulide may increase the antiplatelet activities of Relcovaptan.Investigational
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Nimesulide.Approved
RescinnamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Rescinnamine.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Nimesulide.Approved, Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Nimesulide.Approved, Experimental, Investigational
ReteplaseNimesulide may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Ribostamycin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Nimesulide.Approved
RifampicinThe metabolism of Nimesulide can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Nimesulide can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Nimesulide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Nimesulide can be increased when combined with Rifaximin.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Nimesulide.Approved, Investigational
RimexoloneThe metabolism of Nimesulide can be increased when combined with Rimexolone.Approved
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Nimesulide.Approved
RisedronateThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Risedronate.Approved, Investigational
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Nimesulide.Approved, Investigational
RitanserinRitanserin may increase the antiplatelet activities of Nimesulide.Investigational
RitonavirThe metabolism of Nimesulide can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanNimesulide may increase the anticoagulant activities of Rivaroxaban.Approved
RobenacoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Robenacoxib.Experimental, Vet Approved
RocuroniumNimesulide may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Nimesulide.Approved, Investigational, Withdrawn
RosoxacinNimesulide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinNimesulide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimesulide.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nimesulide.Approved
SaprisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Nimesulide.Experimental
SaquinavirThe metabolism of Nimesulide can be decreased when combined with Saquinavir.Approved, Investigational
SarafloxacinNimesulide may increase the neuroexcitatory activities of Sarafloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Nimesulide.Investigational
SarilumabThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateNimesulide may increase the antiplatelet activities of Sarpogrelate.Investigational
SaruplaseNimesulide may increase the anticoagulant activities of Saruplase.Experimental
SC-236The risk or severity of adverse effects can be increased when Nimesulide is combined with SC-236.Experimental, Investigational
SecobarbitalThe metabolism of Nimesulide can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Nimesulide.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Nimesulide.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Nimesulide.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Nimesulide.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Nimesulide.Approved, Vet Approved
SibutramineSibutramine may increase the antiplatelet activities of Nimesulide.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Nimesulide.Approved
SiltuximabThe serum concentration of Nimesulide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nimesulide can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Sisomicin.Investigational
SitafloxacinNimesulide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Nimesulide.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Nimesulide.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Nimesulide.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Nimesulide.Approved
SotalolNimesulide may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinNimesulide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nimesulide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Nimesulide can be increased when it is combined with Stiripentol.Approved
StreptokinaseNimesulide may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Streptomycin.Approved, Vet Approved
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Nimesulide.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nimesulide.Approved
SulfinpyrazoneNimesulide may increase the antiplatelet activities of Sulfinpyrazone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nimesulide.Approved, Investigational
SulodexideNimesulide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nimesulide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nimesulide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, ANimesulide may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BNimesulide may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusThe risk or severity of renal failure can be increased when Nimesulide is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nimesulide.Approved
TalinololNimesulide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Talniflumate.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nimesulide.Approved, Investigational
TasosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Nimesulide.Approved
Technetium Tc-99m ciprofloxacinNimesulide may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Nimesulide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Nimesulide can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Nimesulide.Approved, Investigational
TemafloxacinNimesulide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Temocapril.Experimental, Investigational
TenecteplaseNimesulide may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tenidap.Experimental
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Nimesulide.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Nimesulide.Approved
Tenofovir disoproxilNimesulide may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nimesulide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Nimesulide.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Nimesulide.Approved
TertatololNimesulide may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneNimesulide may increase the antiplatelet activities of Tesmilifene.Investigational
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Nimesulide.Investigational
ThiamylalThe metabolism of Nimesulide can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nimesulide can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nimesulide.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Nimesulide.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nimesulide.Approved
TiboloneNimesulide may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorNimesulide may increase the antiplatelet activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the antiplatelet activities of Nimesulide.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Nimesulide.Withdrawn
Tiludronic acidThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNimesulide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tinoridine.Investigational
TinzaparinNimesulide may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Tioclomarol.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Nimesulide.Approved
TipranavirTipranavir may increase the antiplatelet activities of Nimesulide.Approved, Investigational
TirofibanTirofiban may increase the antiplatelet activities of Nimesulide.Approved
TixocortolThe risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Nimesulide.Approved, Withdrawn
TobramycinThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Nimesulide can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneThe therapeutic efficacy of Tocopherylquinone can be decreased when used in combination with Nimesulide.Experimental, Investigational
TolazamideThe protein binding of Tolazamide can be decreased when combined with Nimesulide.Approved, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Nimesulide.Approved, Vet Approved
TolbutamideThe protein binding of Tolbutamide can be decreased when combined with Nimesulide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nimesulide.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Nimesulide.Experimental
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Nimesulide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Trandolapril.Approved
TranilastNimesulide may increase the antiplatelet activities of Tranilast.Approved, Investigational
TrapidilNimesulide may increase the antiplatelet activities of Trapidil.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nimesulide.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Nimesulide.Approved, Investigational
TreprostinilThe risk or severity of bleeding can be increased when Treprostinil is combined with Nimesulide.Approved, Investigational
TriamcinoloneThe risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Nimesulide.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nimesulide.Approved, Investigational
TriflusalNimesulide may increase the antiplatelet activities of Triflusal.Approved, Investigational
TrilostaneThe risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Nimesulide.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Nimesulide.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Nimesulide.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nimesulide.Approved
Trolamine salicylateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Nimesulide can be decreased when combined with Troleandomycin.Approved
TrovafloxacinNimesulide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Troxerutin.Investigational
TubocurarineNimesulide may increase the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolThe risk or severity of gastrointestinal irritation can be increased when Ulobetasol is combined with Nimesulide.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nimesulide.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Nimesulide.Investigational
UrokinaseNimesulide may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Nimesulide.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Nimesulide.Approved, Investigational
VancomycinNimesulide may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VecuroniumNimesulide may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nimesulide.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Nimesulide.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Nimesulide.Approved
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Nimesulide.Experimental
Vitamin EVitamin E may increase the antiplatelet activities of Nimesulide.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the antiplatelet activities of Nimesulide.Approved
VoriconazoleThe metabolism of Nimesulide can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Warfarin.Approved
XimelagatranThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Nimesulide.Experimental
ZaltoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zaltoprofen.Approved, Investigational
ZeranolNimesulide may increase the thrombogenic activities of Zeranol.Vet Approved
ZimelidineZimelidine may increase the antiplatelet activities of Nimesulide.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Nimesulide.Approved
ZofenoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nimesulide.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Bernard Pirotte, Geraldine Piel, Philippe Neven, Isabelle Delneuville, Joszef Geczy, "Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses." U.S. Patent US5756546, issued November, 1991.

US5756546
General References
Not Available
External Links
KEGG Drug
D01049
PubChem Compound
4495
PubChem Substance
46507721
ChemSpider
4339
BindingDB
50056999
ChEBI
44445
ChEMBL
CHEMBL56367
Therapeutic Targets Database
DPR000079
PharmGKB
PA137179528
HET
NIM
Drugs.com
Drugs.com Drug Page
Wikipedia
Nimesulide
ATC Codes
M02AA26 — NimesulideM01AX17 — Nimesulide
PDB Entries
1zwp / 2oth / 3e9x / 3n8x / 3ql6 / 4eix
MSDS
Download (23.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailablePain1
2CompletedPreventionCancer, Breast1
3RecruitingTreatmentAcute and Chronic Inflammation / Indigestion1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentPharyngitis1
4WithdrawnTreatmentUpper Respiratory Tract Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)143-144.5 °CPhysProp
logP2.60SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0182 mg/mLALOGPS
logP2.56ALOGPS
logP1.79ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)6.86ChemAxon
pKa (Strongest Basic)-8.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area101.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity76.31 m3·mol-1ChemAxon
Polarizability28.87 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.6341
Caco-2 permeable-0.55
P-glycoprotein substrateNon-substrate0.8267
P-glycoprotein inhibitor INon-inhibitor0.5634
P-glycoprotein inhibitor IINon-inhibitor0.8129
Renal organic cation transporterNon-inhibitor0.8943
CYP450 2C9 substrateNon-substrate0.6235
CYP450 2D6 substrateNon-substrate0.8055
CYP450 3A4 substrateSubstrate0.5257
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7628
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8952
Ames testAMES toxic0.6488
CarcinogenicityNon-carcinogens0.6116
BiodegradationNot ready biodegradable0.9901
Rat acute toxicity3.0832 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5345
hERG inhibition (predictor II)Non-inhibitor0.5574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000x-0291000000-646d9ba99afae997e8ed
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000x-0291000000-d80621f80ce111da876f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0910000000-a5c76988cf3380fc5b30
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-d75eef7fee376750fef9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-3e21c4ed858c88f9fc59
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0459000000-055f5763b37c21230aaa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ue9-2920000000-2d4d6a28e043baa5549a

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Diarylethers / Sulfanilides / Nitrobenzenes / Nitroaromatic compounds / Phenoxy compounds / Phenol ethers / Organic sulfonamides / Organosulfonamides / Aminosulfonyl compounds / Organic oxoazanium compounds
show 6 more
Substituents
Diphenylether / Diaryl ether / Sulfanilide / Nitrobenzene / Phenoxy compound / Nitroaromatic compound / Phenol ether / Organic sulfonic acid amide / Organosulfonic acid amide / Organic sulfonic acid or derivatives
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
C-nitro compound, aromatic ether, sulfonamide (CHEBI:44445)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Rainsford KD: Nimesulide -- a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun;22(6):1161-70. [PubMed:16846549]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phospholipase a2 activity
Specific Function
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name
PLA2G2E
Uniprot ID
Q9NZK7
Uniprot Name
Group IIE secretory phospholipase A2
Molecular Weight
15988.525 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifu...
Gene Name
LTF
Uniprot ID
P02788
Uniprot Name
Lactotransferrin
Molecular Weight
78181.225 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on September 11, 2007 11:49 / Updated on August 02, 2018 05:25